Arcellx, Inc.

ACLXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1786205

Concept	FY2025	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$110.3M	$110.3M	$110.3M	—
Research and Development Expense	$133.8M	$149.6M	$149.6M	$46.9M
Operating Expenses	$200.2M	$191.3M	$191.3M	$65.0M
Operating Income (Loss)	-$89.9M	-$191.3M	-$191.3M	-$65.0M
Other Nonoperating Income (Expense)	$19.9M	$2.6M	$2.6M	$49.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$70.0M	-$188.7M	-$188.7M	—
Income Tax Expense (Benefit)	$663.0K	$663.0K	$663.0K	$0.00
Net Income (Loss) Attributable to Parent	-$70.7M	-$188.7M	-$188.7M	-$65.0M
Earnings Per Share, Basic

Concept	FY2025	FY2024	FY2023	FY2022
Assets	$711.3M	$825.1M	$313.8M	$128.8M
Assets, Current	$599.3M	$716.4M	$266.9M	$112.8M
Cash and Cash Equivalents, at Carrying Value	$105.7M	$394.6M	$64.2M	$30.8M
Liabilities	$256.5M	$339.8M	$108.9M	$16.9M
Liabilities, Current	$125.4M	$118.2M	$56.7M	$14.8M
Accounts Payable, Current	$2.1M	$2.6M	$9.1M	$1.3M
Stockholders' Equity Attributable to Parent	-$205.0M	-$121.5M	-$121.5M	-$63.7M
Common Stock, Shares, Outstanding	$54.3M	$52.3M	$44.1M	$544.2K

Concept	FY2025	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	$207.6M	-$99.3M	-$99.3M	-$54.2M
Net Cash Provided by (Used in) Investing Activities	-$154.5M	-$117.7M	-$117.7M	-$80.0M
Net Cash Provided by (Used in) Financing Activities	$279.2M	$252.6M	$252.6M	$118.5M
Payments to Acquire Property, Plant, and Equipment	$21.4M	$2.3M	$2.3M	$5.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)